HR and breast cancer: Patients with ET-resistant, PIK3CA-mutated, HR+/HER2− locally advanced or metastatic treatment-naïve breast cancer were recently evaluated in the INAVO120 phase III clinical trial that compared inavolisib, a PI3Kα inhibitor, in combination with palbociclib and fulvestrant with standard-of-care palbociclib plus fulvestrant.